Evidence map›Paper›PMID 39777251›Full record

ReviewWorld journal of gastroenterology2025

Creeping fat and gut microbiota in Crohn's disease.

Ana Ev Quaglio, Daniéla O Magro, Marcello Imbrizi, Ellen Cs De Oliveira, Luiz C Di Stasi, Ligia Y Sassaki

Abstract readReview
In one paragraph

Review in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. A Developmental Perspective on the Intestinal Microbiota in Crohn's Disease.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ana Ev QuaglioVerum Ingredients, Botucatu Technology Park, Botucatu 18605-525, São Paulo, Brazil.
Daniéla O MagroDepartment of Surgery, Faculty of Medical Sciences, State University of Campinas, Campinas 13083-970, São Paulo, Brazil.
Marcello ImbriziDepartment of Gastroenterology, Faculty of Medical Sciences, University of Campinas, Campinas 13083-970, São Paulo, Brazil.
Ellen Cs De OliveiraDepartment of Internal Medicine, Medical School, São Paulo State University, Botucatu 18618-686, São Paulo, Brazil.
Luiz C Di StasiDepartment of Biophysics and Pharmacology, Institute of Biosciences, São Paulo State University, Botucatu 18618-689, São Paulo, Brazil.
Ligia Y SassakiDepartment of Internal Medicine, Medical School, São Paulo State University, Botucatu 18618-686, São Paulo, Brazil. ligia.sassaki@unesp.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this article, we explored the role of adipose tissue, especially mesenteric adipose tissue and creeping fat, and its association with the gut microbiota in the pathophysiology and progression of Crohn's disease (CD). CD is a form of inflammatory bowel disease characterized by chronic inflammation of the gastrointestinal tract, influenced by genetic predisposition, gut microbiota dysbiosis, and environmental factors. Gut microbiota plays a crucial role in modulating immune response and intestinal inflammation and is associated with the onset and progression of CD. Further, visceral adipose tissue, particularly creeping fat, a mesenteric adipose tissue characterized by hypertrophy and fibrosis, has been implicated in CD pathogenesis, inflammation, and fibrosis. The bacteria from the gut microbiota may translocate into mesenteric adipose tissue, contributing to the formation of creeping fat and influencing CD progression. Although creeping fat may be a protective barrier against bacterial invasion, its expansion can damage adjacent tissues, leading to complications. Modulating gut microbiota through interventions such as fecal microbiota transplantation, probiotics, and prebiotics has shown potential in managing CD. However, more research is needed to clarify the mechanisms linking gut dysbiosis, creeping fat, and CD progression and develop targeted therapies for microbiota modulation and fat-related complications in patients with CD.

Indexed as

Crohn DiseaseDisease ProgressionDysbiosisFecal Microbiota TransplantationGastrointestinal MicrobiomeIntra-Abdominal FatProbioticsAnimalsFibrosisHumansMesenteryPrebioticsPrebioticsCreeping fatCrohn’s diseaseGut microbiotaInflammatory bowel diseaseMesenteric adipose tissue

Identifiers

PMID39777251
PMCPMC11684179

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.